» Articles » PMID: 16192453

Absence of Kaposi's Sarcoma-associated Herpesvirus in Patients with Pulmonary Arterial Hypertension

Overview
Specialty Critical Care
Date 2005 Sep 30
PMID 16192453
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale: In addition to Kaposi's sarcoma, Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8) has been associated with two other diseases: primary effusion lymphoma and the plasma cell variant of multicentric Castleman's disease. Recently, evidence of KSHV infection was reported in plexiform lesions of idiopathic pulmonary arterial hypertension (IPAH) as well as in adjacent parenchyma and bronchial epithelial cells.

Objectives: To further investigate a possible association of KSHV and pulmonary arterial hypertension.

Methods And Measurements: Twenty-six lungs explanted from German patients suffering from IPAH were tested for the presence of KSHV antigen and genomes by immunohistochemistry (IHC) and polymerase chain reaction (PCR).

Main Results: When stained with a commercial monoclonal antibody directed against the latency-associated nuclear antigen of KSHV, LANA-1, a positive signal reminiscent of the "speckled" nuclear pattern typical of latently KSHV-infected cells was found in 16 (61.5%) cases. Alveolar and bronchial epithelial cells in areas of unremarkable lung tissue, but not cells within the plexiform lesions, were the predominantly stained cell types. Different KSHV-PCR assays (based on orf26, orfK6, and orf72) performed on samples that had tested positively in IHC, however, could not confirm KSHV infection, indicating that the IHC signal was not due to KSHV infection. One IHC-negative patient tested positive by PCR. A PCR based on consensus degenerate hybrid oligonucleotide primers (CODEHOP) to detect yet unknown gamma-herpesviruses did not reveal any specific sequences.

Conclusions: KSHV is unlikely to play a role in the pathogenesis of IPAH.

Citing Articles

The Role of Bone Morphogenetic Protein Receptor Type 2 () and the Prospects of Utilizing Induced Pluripotent Stem Cells (iPSCs) in Pulmonary Arterial Hypertension Disease Modeling.

Devendran A, Kar S, Bailey R, Trivieri M Cells. 2022; 11(23).

PMID: 36497082 PMC: 9741276. DOI: 10.3390/cells11233823.


The Third Man: DNA sensing as espionage in pulmonary vascular health and disease.

Bryant A, Pham A, Gogoi H, Mitchell C, Pais F, Jin L Pulm Circ. 2021; 11(1):2045894021996574.

PMID: 33738095 PMC: 7934053. DOI: 10.1177/2045894021996574.


Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus.

Dunmore B, Jones R, Toshner M, Upton P, Morrell N Cardiovasc Res. 2021; 117(11):2309-2325.

PMID: 33399862 PMC: 8479804. DOI: 10.1093/cvr/cvaa350.


Association of COVID-19 and other viral infections with interstitial lung diseases, pulmonary fibrosis, and pulmonary hypertension: A narrative review.

Atabati E, Dehghani-Samani A, Mortazavimoghaddam S Can J Respir Ther. 2020; 56:1-9.

PMID: 33274259 PMC: 7690312. DOI: 10.29390/cjrt-2020-021.


Human Endogenous Retrovirus K and Pulmonary Arterial Hypertension: A New Take on a Retro Idea.

Culley M, Chan S Circulation. 2017; 136(20):1936-1938.

PMID: 29133530 PMC: 6467572. DOI: 10.1161/CIRCULATIONAHA.117.031190.